Medicare Payment Policy and Recombinant Erythropoietin Prescribing for Dialysis Patients
Open Access
- 1 October 1993
- journal article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 22 (4) , 557-567
- https://doi.org/10.1016/s0272-6386(12)80929-2
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Early dosing practices and effectiveness of recombinant human erythropoietinKidney International, 1993
- Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing HomesNew England Journal of Medicine, 1991
- Biotechnology — The Enormous Cost of SuccessNew England Journal of Medicine, 1991
- ErythropoietinNew England Journal of Medicine, 1991
- Recombinant Human Erythropoietin and Renal Anemia: Molecular Biology, Clinical Efficacy, and Nervous System EffectsAnnals of Internal Medicine, 1991
- Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessmentBritish Journal of Haematology, 1990
- The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human ErythropoietinJAMA, 1990
- The Effect of the Medicare Prospective Payment System on the Adoption of New TechnologyNew England Journal of Medicine, 1989
- Payment Restrictions for Prescription Drugs under MedicaidNew England Journal of Medicine, 1987
- SURGICAL TREATMENT OF PEPTIC ULCER IN THE UNITED STATESThe Lancet, 1981